2012
DOI: 10.1016/j.ijoa.2011.10.001
|View full text |Cite
|
Sign up to set email alerts
|

Effect of μ-opioid receptor A118G polymorphism on the ED50 of epidural sufentanil for labor analgesia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
10
2

Year Published

2012
2012
2025
2025

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(13 citation statements)
references
References 15 publications
1
10
2
Order By: Relevance
“…These data demonstrated a similar pharmacogenetic association of A118G genotype with neuraxial opioid potency during labor analgesia, although with a more modest clinical effect [23].…”
Section: Oprm1 and Epidural Sufentanil For Labor Analgesiasupporting
confidence: 57%
See 1 more Smart Citation
“…These data demonstrated a similar pharmacogenetic association of A118G genotype with neuraxial opioid potency during labor analgesia, although with a more modest clinical effect [23].…”
Section: Oprm1 and Epidural Sufentanil For Labor Analgesiasupporting
confidence: 57%
“…Lower ED50 in women with G118 allele [23] OPRM1 A118G Labor pain and progress (N = 65, North American)…”
Section: Comt Val158metmentioning
confidence: 99%
“…The results demonstrated a significant difference between poor metabolizers, extensive metabolizers, and ultra-rapid metabolizers area under the curves (AUCs) of morphine with a median (range) AUC of 0.5 mg h/l (0.5-2.8) in poor metabolizers, 11 mg h/l (5-17) mg h/l in extensive metabolizers, and 16 (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) mg h/l in ultra-rapid metabolizers (P ¼ 0.02). The O-demethylation of codeine to morphine is mediated by CYP2D6.…”
Section: Cytochrome 2d6mentioning
confidence: 99%
“…OPRM1 is known to display several single nucleotide polymorphisms (SNPs). There is great interest in one common polymorphism of OPRM1, p. 118A/G, because the G118 allele has been shown to reset in the substitution of amino acid asparagine with aspartate at position 40 (Camorcia et al, 2012). Due to this discovery many clinical trials were conducted with following findings.…”
Section: Variability In Pharmacodynamic Characteristicsmentioning
confidence: 99%